Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I ...
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer | Future Oncology
The Time Course of Adverse Events During Dostarlimab Treatment in Patients with Recurrent or Advanced Endometrial Cancer in the
GARNET Clinical Trial Regimen in Advanced Disease
Immune-Related End Points Consistent With Traditional Measurements of Dostarlimab in Non-Endometrial dMMR Solid Tumors
Plain language summary of the GARNET trial: clinical activity and safety of dostarlimab for recurrent or advanced dMMR endometrial cancer patients - Oncology Central
Expert Commentary On The Product Profile Of Dostarlimab
PDF) 76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in
ESGO 2022: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study
Biosensors | Free Full-Text | Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
GARNET: Dostarlimab in EC - Slideset Download - Clinical Oncology 2022 | CCO
GARNET Study Suggests Dostarlimab Promising for Uterine/Endometrial Cancer - CancerConnect
On the ground at ASCO: two VHIO-led studies show the promise of immunotherapy for the treatment of advanced endometrial and cervical cancer - Biotech Spain
Dostarlimab subject to accelerated FDA approval for the treatment of advanced dMMR endometrial cancer | VJOncology
Current Oncology | Free Full-Text | Endometrial Cancer: Transitioning from Histology to Genomics
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis - Gynecologic Oncology
GSK Poster Hub
Current Oncology | Free Full-Text | Endometrial Cancer: Transitioning from Histology to Genomics
From New Molecular Insights to New Treatment Options in Endometrial Cancer | Published in healthbook TIMES Oncology Hematology
Dostarlimab: First Approval | SpringerLink
Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study - ScienceDirect
Medicina | Free Full-Text | Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
